日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report

在接受menin抑制剂治疗前,NPM1突变或KMT2A重排的AML老年患者的临床结局:Beat AML报告

Zeidner, Joshua F; Jain, Jayanshu; Welkie, Rina Li; Huang, Ying; Swords, Ronan T; Traer, Elie; Stein, Eytan M; Lin, Tara L; Madanat, Yazan F; Collins, Robert H; Baer, Maria R; Duong, Vu H; Blum, William G; Arellano, Martha L; Stock, Wendy; Odenike, Olatoyosi; Olin, Rebecca L; Smith, Catherine C; Foran, James M; Schiller, Gary J; Curran, Emily K; Handa, Shivani; Heerema, Nyla A; Chen, Timothy; Martycz, Molly; Stefanos, Mona; Marcus, Sonja G; Rosenberg, Leonard; Druker, Brian J; Levine, Ross L; Burd, Amy; Yocum, Ashley O; Mims, Alice S; Byrd, John C; Borate, Uma

DDX41-Mutated AML: A Case Report and Perspectives

DDX41突变型急性髓系白血病:病例报告及展望

Yashar, William M; Eide, Christopher A; Kurtz, Stephen E; Long, Nicola; Johnson, Kara J; Tognon, Cristina E; Druker, Brian J; Tyner, Jeffrey W; Swords, Ronan

Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia

一项评估鲁索替尼联合维奈托克治疗复发/难治性急性髓系白血病患者的1期临床试验结果

Borate, Uma; Tognon, Cristina E; Madanat, Yazan F; Misra, Shikha; Kaempf, Andy; Patel, Prapti A; Davis, Kara L; Sun, Junwei; Stuani, Lucille; Eisenmann, Eric D; Eide, Christopher A; Kurtz, Stephen E; Watanabe-Smith, Kevin; Johnson, Kara; Jager, Astraea; Gullaksen, Stein-Erik; Robinson, Bridget; Vu, Tania; Plevritis, Sylvia K; Baker, Sharyn D; Minnier, Jessica; Clement, Peter; Avaylon, Sammantha; Hayes, Madison; Newell, Laura F; Gandhi, Arpita P; Leonard, Jessica; Hayes-Lattin, Brandon; Vasu, Sumithira; Cook, Rachel J; Meyers, Gabrielle; Maziarz, Richard T; Traer, Elie; Swords, Ronan; Tyner, Jeffrey W; Druker, Brian J; Saultz, Jennifer N

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML

阿扎胞苷、维奈托克和瑞伐美尼用于新诊断的NPM1突变或KMT2A重排急性髓系白血病

Zeidner, Joshua F; Lin, Tara L; Welkie, Rina Li; Curran, Emily; Koenig, Kristin; Stock, Wendy; Madanat, Yazan F; Swords, Ronan; Baer, Maria R; Blum, William; Stein, Eytan M; Olin, Rebecca L; Schiller, Gary; Nichols, Angela; Odenike, Olatoyosi; Traer, Elie; Lachowiez, Curtis; Duong, Vu H; Hochman, Michael J; Cai, Sheng F; Smith, Catherine; Stefanos, Mona; Martycz, Molly; Huang, Ying; Rosenberg, Len; Marcus, Sonja; Chen, Timothy L; Yocum, Ashley O; Druker, Brian J; Levine, Ross L; Borate, Uma; Byrd, John C; Mims, Alice S

A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia

CEBPB/IL-1β/TNF-α反馈环路驱动单核细胞白血病对维奈托克和MDM2抑制剂的耐药性

Allen, Basil; Bottomly, Daniel; Köhnke, Thomas; Wang, Anthony; Lin, Hsin-Yun; Johnson, Kara; Kenna, Isabel; Streltsova, Anastatia; Martin, Emma; Chen, Reid; Savoy, Lindsey; Long, Nicola; Ryabinin, Peter; Kurtz, Stephen E; Eide, Christopher A; Carlos, Amy; Kaempf, Andy; Liu, Tingting; Tognon, Cristina; Searles, Robert; Piehowski, Paul D; Gosline, Sara J C; Agarwal, Anupriya; Chang, Bill H; Barton, Michelle; Druker, Brian J; McWeeney, Shannon K; Majeti, Ravindra; Tyner, Jeffrey W; Zhang, Haijiao

Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial

对60岁及以上新诊断急性髓系白血病患者进行分子特征分析:来自Beat AML临床试验的报告

Hoff, Fieke W; Huang, Ying; Welkie, Rina Li; Swords, Ronan T; Traer, Elie; Stein, Eytan M; Lin, Tara L; Patel, Prapti A; Collins, Robert H Jr; Baer, Maria R; Duong, Vu H; Blum, William G; Arellano, Martha L; Stock, Wendy; Odenike, Olatoyosi; Redner, Robert L; Kovacsovics, Tibor; Deininger, Michael W; Zeidner, Joshua F; Olin, Rebecca L; Smith, Catherine C; Foran, James M; Schiller, Gary J; Curran, Emily K; Koenig, Kristin L; Heerema, Nyla A; Chen, Timothy; Martycz, Molly; Stefanos, Mona; Marcus, Sonja G; Rosenberg, Leonard; Druker, Brian J; Levine, Ross L; Burd, Amy; Yocum, Ashley O; Borate, Uma M; Mims, Alice S; Byrd, John C; Madanat, Yazan F

Oncogenic NTRK3 mutations exhibit differential sensitivity to tropomyosin receptor kinase inhibitors in patients with acute myeloid leukemia

致癌性 NTRK3 突变在急性髓系白血病患者中对原肌球蛋白受体激酶抑制剂表现出不同的敏感性。

Joshi, Sunil K; Huang, Ariane; Pittsenbarger, Janét; Shinde, Ujwal; Posso, Camilo; Piehowski, Paul D; Gosline, Sara J C; Press, Richard D; Gritsenko, Marina A; Hutchinson, Chelsea; Weitz, Karl K; Watanabe-Smith, Kevin; Long, Nicola; Rodland, Karin D; Tyner, Jeffrey W; Druker, Brian J; Tognon, Cristina E

Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib.

髓系和淋巴系细胞中癌蛋白 TEL-ABL 的自身磷酸化赋予了对变构 ABL 抑制剂 asciminib 的耐药性

Muratcioglu Serena, Eide Christopher A, Hung Chien-Lun, Gorday Kent, Sumpena Emily, Zuo Wenqi, Groves Jay T, Druker Brian J, Kuriyan John

The aryl hydrocarbon receptor is associated with monocytic AML and innate immune resistance reversible with an AHR inhibitor.

芳烃受体与单核细胞性急性髓系白血病和先天性免疫抵抗有关,而这种抵抗可以通过 AHR 抑制剂逆转。

Saultz Jennifer N, Bottomly Daniel, Burns Faith, Byrd Kaelan, Kosaka Yoko, Alber Bernhard, Chandra Daniel, Kurtz Stephen E, Fan Guang, Kaempf Andy, Long Nicola, Sanchez-Martin Marta, Wang Lei, McGovern Karen, Kaufman Dan S, McWeeney Shannon K, Druker Brian J, Tyner Jeffrey W, Lind Evan F

A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

一项针对 60 岁及以上未经治疗的急性髓系白血病患者,评估 TP-0903 和地西他滨靶向突变型 TP53 和/或复杂核型的 1b/2 期研究

Eisenmann, Eric D; Swords, Ronan; Huang, Ying; Orwick, Shelley; Buelow, Daelynn; Abbott, Nicole; Phelps, Mitch; Zeidner, Joshua; Foster, Matthew C; Lin, Tara L; Baer, Maria R; Madanat, Yazan F; Kovacsovics, Tibor; Redner, Robert; Al-Mansour, Zeina; Bhatnagar, Bhavana; Stefanos, Mona; Martycz, Molly; Druggan, Franchesca; Chen, Timothy L; Yocum, Ashley O; Borate, Uma; Druker, Brian J; Burd, Amy; Levine, Ross L; Byrd, John C; Baker, Sharyn D; Mims, Alice S